Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - Priority Announcement: Aging (Bridge Funding)

University of British Columbia

$100,000.00

Pathogenesis of age related macular degeneration (AMD)

EF 2008-09

Résumé
Age related macular degeneration (AMD) is the most common cause of irreversible vision loss in the elderly. Each year almost 80,000 Canadians are diagnosed with some form of AMD. At present, there are an estimated 1 million people in Canada with AMD, and that number is expected to double by 2031. There are treatments to slow the progression of vision loss, but unfortunately, there are no cures available for AMD. In order to develop cures, further information about how and why AMD develops is needed. Two important factors associated with disease progression are oxidative stress and inflammation. Oxidative stress has been implicated in AMD, and results from a ten-year clinical study sponsored by the National Eye Institute (NEI, AREDs) reported that high dose antioxidant supplements significantly reduce the risk of advanced AMD by about 25 percent. Inflammation has also been implicated as several labs have demonstrated a strong association between polymorphisms of the complement factor H gene and AMD disease progression. The proposed studies will focus on two candidate triggers of oxidative stress and inflammation in the retina: amyloid beta (A-beta) and advanced glycation endproducts (AGEs). Both A-beta and AGEs are constituents of drusen, the hallmark extracellular deposits of the 'dry' form of AMD. Both have been associated with oxidative stress and inflammatory processes in diseases of the brain and eye, including Alzheimer, AMD and diabetic retinopathy. The proposed studies will allow the development of new treatment regimens that target retinal inflammation and thus minimize the processes that 'trigger' the onset of macular degeneration.
Programme
Operating Grant - Priority Announcement: Aging (Bridge Funding)
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
176030
Name
Matsubara Joanne A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Clinical Investigation - A: Reproduction, Maternal, Child and Youth Health
Projecttitle
Pathogenesis of age related macular degeneration (AMD)
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Aging (Bridge Funding)
Keyworddelim
Advanced Glycation Endproducts; Age Related Macular Degeneration; Alzheimer'S Disease; Amyloid Beta; Chronic Inflammation; Drusen
Abstract
Age related macular degeneration (AMD) is the most common cause of irreversible vision loss in the elderly. Each year almost 80,000 Canadians are diagnosed with some form of AMD. At present, there are an estimated 1 million people in Canada with AMD, and that number is expected to double by 2031. There are treatments to slow the progression of vision loss, but unfortunately, there are no cures available for AMD. In order to develop cures, further information about how and why AMD develops is needed. Two important factors associated with disease progression are oxidative stress and inflammation. Oxidative stress has been implicated in AMD, and results from a ten-year clinical study sponsored by the National Eye Institute (NEI, AREDs) reported that high dose antioxidant supplements significantly reduce the risk of advanced AMD by about 25 percent. Inflammation has also been implicated as several labs have demonstrated a strong association between polymorphisms of the complement factor H gene and AMD disease progression. The proposed studies will focus on two candidate triggers of oxidative stress and inflammation in the retina: amyloid beta (A-beta) and advanced glycation endproducts (AGEs). Both A-beta and AGEs are constituents of drusen, the hallmark extracellular deposits of the 'dry' form of AMD. Both have been associated with oxidative stress and inflammatory processes in diseases of the brain and eye, including Alzheimer, AMD and diabetic retinopathy. The proposed studies will allow the development of new treatment regimens that target retinal inflammation and thus minimize the processes that 'trigger' the onset of macular degeneration.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Matsubara, Joanne A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~